A phase II trial with mirdametinib, a MEK inhibitor, for adolescents and young adults with NF1-associated plexiform neurofibromas showed a 42% partial response and a significant decrease in pain ratings [56]. Here, MAP2K7 is linked to plexiform neurofibroma.